2019 U.S.-Booked Air Volume: $54 million
Primary Global Expense Supplier: Concur
Travel Risk Management Supplier: WorldAware
In 2019, pharmaceutical company Takeda spent $54 million on U.S.-booked air, up from $2 million in 2018. However, Takeda expects its U.S.-booked air spend to plummet to $23 million for 2020. Takeda has a single global travel policy and a single U.S. travel policy. Twenty-one percent of the company's U.S.-booked air was for domestic travel. The company is in the process of consolidating to one global travel management company and will complete this initiative in 2021.
In January of 2019, Takeda completed its acquisition of biopharmaceutical company Shire. Since the acquisition, the travel team has harmonized policy and processes globally as part of the “One Takeda” transformation and integration. In partnership with the global procurement department, the team prepared and launched a global TMC RFP for more than 70 countries. The team harmonized air, car and hotel contracts across the global organization, employing a “do no harm” strategy. It also participated in a global corporate card alignment project.
In addition to working toward a consolidated TMC partnership, Takeda expanded its existing travel reporting capabilities in 2020 through the design and build of a multisource global travel data warehouse. The company has architected a global travel brand strategy, return-to-travel guidelines and a mobile strategy to achieve an end-to-end digital travel experience.